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Abstract
Multiple system atrophy is a parkinsonian neurodegenerative disorder. It is cytopathologically characterized by
accumulation of the protein p25a in cell bodies of oligodendrocytes followed by accumulation of aggregated a-synuclein
in so-called glial cytoplasmic inclusions. p25a is a stimulator of a-synuclein aggregation, and coexpression of a-synuclein
and p25a in the oligodendroglial OLN-t40-AS cell line causes a-synuclein aggregate-dependent toxicity. In this study, we
investigated whether the FAS system is involved in a-synuclein aggregate dependent degeneration in oligodendrocytes
and may play a role in multiple system atrophy. Using rat oligodendroglial OLN-t40-AS cells we demonstrate that the
cytotoxicity caused by coexpressing a-synuclein and p25a relies on stimulation of the death domain receptor FAS and
caspase-8 activation. Using primary oligodendrocytes derived from PLP-a-synuclein transgenic mice we demonstrate that
they exist in a sensitized state expressing pro-apoptotic FAS receptor, which makes them sensitive to FAS ligand-mediated
apoptosis. Immunoblot analysis shows an increase in FAS in brain extracts from multiple system atrophy cases.
Immunohistochemical analysis demonstrated enhanced FAS expression in multiple system atrophy brains notably in
oligodendrocytes harboring the earliest stages of glial cytoplasmic inclusion formation. Oligodendroglial FAS expression is
an early hallmark of oligodendroglial pathology in multiple system atrophy that mechanistically may be coupled to a-
synuclein dependent degeneration and thus represent a potential target for protective intervention.
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Introduction
Multiple system atrophy (MSA) is a sporadic and progressive
neurodegenerative disease that presents with motor abnormalities
like akinesia, rigidity and postural instability. No effective
symptomatic treatment is currently available. Unlike the other
a-synucleinopathies of Parkinson’s disease (PD) and dementia with
Lewy bodies (DLB), which are characterized by neuronal
aggregates of a-synuclein (a-syn), MSA is neuropathologically
characterized by glial cytoplasmic inclusions (GCIs) containing
aggregated a-syn in oligodendrocytes [1,2,3]. The presence of a-
syn in oligodendrocytes is enigmatic as these cells do not normally
express a-syn, but its accumulation may be due to aberrant
expression or transcellular uptake from neurons. Still, the
pathogenic potential of a-syn in oligodendrocytes has been
demonstrated in transgenic (tg) mice overexpressing human a-
syn under the control of oligodendrocyte-specific promoters
[CNPase, MBP and PLP] [4,5,6]. These tg mice develop a-syn
accumulations in oligodendrocytes and exhibit oligodendroglial
and neuronal pathology or increased sensitivity to toxins [7,8].
Changes in oligodendrocyte morphology are observed in MSA
prior to a-syn accumulation and aggregation. These changes
comprise proteolysis of myelin basic protein (MBP) in myelin and
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enlargement of oligodendroglial cell bodies with accumulation of
the oligodendrocyte-specific protein p25a prior to the accumula-
tion of a-syn [9].
In addition to oligodendrocytic myelin loss and a-syn accumu-
lation, MSA patients display considerable neuronal loss accom-
panied by astrogliosis and microgliosis [10,11]. This is recapitu-
lated in tg mouse models overexpressing human a-syn in
oligodendrocytes [5,6]. In vivo and in vitro studies of MBP-ha-syn
mice and primary oligodendrocytes from CNPase-ha-syn mice
point to a pathogenic role of transcellular secretory substances
[12,13]. FAS (CD95) is a plasma membrane death domain
receptor that activates the extrinsic apoptotic pathway upon
interaction with the FAS ligand (FASL) and plays an important
role in immune-related cell removal [14]. FAS has also been
implicated in degenerative processes in the central nervous system
in general [15] and in oligodendrocyte cell death in an
experimental model of multiple sclerosis (MS) [16].
In the present study, we demonstrate a functional role of
autocrine signaling through FAS in the degenerative pathway of a-
syn aggregation in the oligodendroglial OLN cell line. Primary
oligodendrocytes from ha-syn tg mice [4] display a-syn-dependent
sensitization to the apoptotic effect of FASL. Analysis of post
mortem MSA tissue demonstrates an increased FAS expression in
brain homogenates and in oligodendrocytes containing early-stage
GCIs. We hypothesize that autocrine and paracrine FAS signaling
may represent an active contributor to the neurodegeneration
observed in MSA.
Materials and Methods
Plasmids and transfection
pcDNA3.1 zeo(-) plasmid expressing human p25a was pro-
duced by PCR with pET-11d vector containing the human p25a
Figure 1. a-synuclein dependent degeneration in OLN-93 cells
requires FAS signaling and caspase-8 activation. OLN-t40-AS
cells stably expressing human a-syn were treated with peptide
aldehyde inhibitors (20 mM) against caspase-3 (Ac-DEVD-CHO), cas-
pase-8 (Ac-IETD-CHO), caspase-9 (Ac-LEHD-CHO) and FAS-blocking
antibody (ZB4) (1 mg/ml) 1 h prior to transfection with p25a. MT
retraction was quantified my immunofluorescence microscopy 24 h
after transfection. Bars represent the mean 6 standard error of mean
(SEM) from three independent experiments. Inhibition of caspase-3,
caspase-8 and FAS but not caspase-9 caused a significant reduction in
MT retraction as compared with the control cells (p,0.05 with respect
to untreated cells).
doi:10.1371/journal.pone.0055243.g001
Figure 2. a-synuclein expressing oligodendrocytes are sensi-
tized to FAS-dependent toxicity. A, In vitro differentiation of (PLP)-
a-syn tg oligodendrocytes. Oligodendrocyte progenitor cells were
isolated from tg mouse forebrains and cultured for the indicated times.
Cells were fixed for double-label immunostaining with antibodies
against A2B5, NG2, O4, GalC and MBP (green; left panels) as well as
monoclonal 15G7 against human a-syn (red; right panels). Differenti-
ated cells (7 DIV) were immunostained with an antibody against p25a
and visualized by phase contrast microscopy. Scale bars, 10 mm. B,
Human a-syn and eGFP tg oligodendrocytes were treated for 24 h with
DMSO (control), sFASL, mFASL or preincubated for 30 min with FAS-
blocking antibody before challenge with mFASL. Cells were fixed and
labeled with O4 and Hoechst. mFASL treatment induced oligodendro-
cyte cell death as determined by apoptotic nuclei with a-syn
oligodendrocytes being significantly more sensitive to FAS mediated
cell death than eGFP oligodendrocytes. Data represent mean 6 SEM of
total tg oligodendrocytes from three independent experiments.
Student t test (n= 3): *p,0.0001 compared with untreated cultures;
#p,0.001 compared with eGFP tg cultures exposed to the same
challenge. Western blots prepared from lysates of wild-type and a-syn
tg oligodendrocyte cultures were sequentially probed with monoclonal
anti-FAS and anti-a-tubulin antibodies (insert).
doi:10.1371/journal.pone.0055243.g002
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gene as template [17]. The product was inserted into pcDNA3.1
zeo(-) vector, which was transformed into competent E. coli DH5a
cells to select positive clones for sequencing. The chosen clones
were cultured and plasmid DNA was purified. The construct was
confirmed by sequencing. Transient transfections were performed
with Fugene-6 Transfection Reagent (Roche, Mannheim, Ger-
many) according to the manufacturer’s protocol.
Oligodendrocyte cell line experimentation
OLN-t40-AS rat oligodendroglial cells are based on the OLN-
93 cell line derived from primary Wistar rat brain glial cultures
[18]. Cells were kept at 37uC under 5% CO2 and grown in
DMEM (Lonza, Verviers, Belgium) supplemented with 10% foetal
calf serum (FCS), 50 U/ml of penicillin and 50 mg/ml of
streptomycin. OLNt40AS cells were maintained in 50 mg/ml
geneticin. These cells express human a-syn and develop a-syn
aggregate-dependent degeneration upon coexpression with the
pro-aggregatory p25a protein [19].
For inhibition of caspase activity, cells were treated with 20 mM
of caspase-3, -8, and -9 inhibitors, Ac-DEVD-CHO, Ac-IETD-
CHO or Ac-LEHD-CHO (Bachem, Weil am Rhein, Germany),
for 1 h prior to transfection with p25a and during the post
transfection period. For inhibition of FAS signaling, cells were
pretreated with 1 mg/ml of mouse monoclonal anti-FAS antibody
(clone ZB4, Upstate Biotechology, Temecula, USA) for 1 h prior
to transfection with p25a and during the post transfection period.
a-Syn aggregate-dependent degeneration was quantified by
measuring the development of microtubule (MT) retraction in
OLN-t40-AS cells expressing p25a as previously described [19]. In
brief, cells were processed for immunofluorescence microscopy
using rabbit polyclonal anti-p25a antibody [17] and mouse
monoclonal anti-a-tubulin (Sigma, Steinhelim, Germany), coun-
terstained with DAPI and analyzed by fluorescence microscopy.
MT retraction was defined as a retraction of MT from the cellular
processes to the perinuclear region resulting in intense a-tubulin
staining surrounding the nucleus. MT retraction was quantified by
counting p25a-positive cells with a clear perinuclear localization of
MT compared to the total number of p25a-positive cells. In each
experiment, 200 transfected cells localized in five randomly chosen
microscopic fields were examined at 100 times magnification.
Two independent investigators counted the cells blind to treatment
conditions. Student’s t test was used to determine whether
differences between groups were significant.
Purification and culturing of oligodendrocytes
Transgenic oligodendrocyte progenitor cells were purified from
perinatal (PLP)- a-syn, (PLP)-eGFP and WT C57Bl6 mouse brain
as previously described [20]. Briefly, mixed glial cultures were
obtained from two days old mouse forebrains. Mice were killed by
decapitation, and forebrains were dissected before being dissoci-
ated, first mechanically and then by digestion with 0.1% trypsin
(15 min at 37uC). Cells were washed in Hank’s balanced salt
solution, passed through 150 mm and 63 mm nylon meshes and
layered on a percoll density gradient. The oligodendrocyte
progenitor-enriched fraction was then centrifuged and resus-
pended in DMEM containing 10% FCS. Cells were plated onto
poly-L-lysine coated glass coverslips or plastic 24-well plates for
20 min at 37uC in an atmosphere containing 5% CO2 to allow cell
adhesion. 500 mL of Bottenstein and Sato medium, supplemented
with 1% FCS, 1% penicillin-streptomycin and 10 ng/ml recom-
binant platelet-derived growth factor (PDGF)-AA (Peprotech) was
added to the oligodendrocyte progenitor cultures. After 7 days in
culture, the medium was changed to a differentiating medium
(proliferating medium without PDGF).
To stimulate the extrinsic apoptotic pathway, oligodendrocyte
cultures were treated for 18 h with 5 ng/ml soluble FAS ligand
(sFASL) or membrane-bound FAS ligand (mFASL) (Upstate
Biotechnology). To block signaling through the FAS receptor,
cells were preincubated with neutralizing anti-FAS antibody
(1 mg/ml) (clone ZB4). Cells were stained with Hoechst (Sigma)
to identify apoptotic nuclei. For quantitative assessments, 500
oligodendrocytes from three randomly selected fields were
analyzed. Student’s t tests or one-way ANOVA followed by
Dunnett’s test were used to determine whether differences between
groups were significant.
Immunocytochemistry
For double immunostaining of surface and cytoplasmic
antigens, cultures were rinsed once with phosphate-buffered saline
(PBS), and fixed with 4% paraformaldehyde in PBS for 5 min at
room temperature (RT). After washing with PBS, fixed cells were
blocked with 10% FCS for 30 min and incubated overnight at 4uC
with primary antibodies diluted in blocking solution. For double
immunostaining involving only cytoplasmic antigens, cultures
were rinsed once with PBS and fixed with 4% paraformaldehyde
in PBS for 15 min at RT. After washing with PBS, fixed cells were
blocked with 10% FCS in PBS for 30 min and incubated for 1 h
with primary antibodies diluted in blocking solution containing
0.02% Triton-X-100. Cells were washed, incubated for 1 h with
secondary antibodies and counterstained with Hoechst 33342. To
examine the extent of non-specific binding, primary antibody was
omitted. After washing in PBS, coverslips were mounted in
fluoromount (Southern Biotechnology Associates).
Cells were assessed using an Eclipse TE300 fluorescence
microscope (Nikon) and 20X or 40X objectives, with phase
contrast microscopy performed with a 40X objective. Images were
acquired with simple PCI software (Compic Inc. Imaging
Systems). To demonstrate co-localization, cells were visualized
using 63X or 100X oil-immersion objectives with an axioplan2
imaging Zeiss microscope or with an LSM510 Zeiss confocal
Figure 3. FAS is upregulated in human MSA brain. A, B, Immunohistochemical staining for FAS in normal controls. In normal controls there
were only occasional FAS-positive cells shown here in (A) the inferior temporal cortical white matter and (B) grey matter. Insert in (A) shows a FAS-
positive cell resembling a microglia. C–H, Immunohistochemical staining for FAS in MSA cases. MSA tissue contained numerous FAS-positive glial
cells shown here in the inferior temporal cortical (C) white matter and (D) grey matter. Arrows indicate FAS-positive oligodendrocytes, and
arrowheads indicate FAS-positive astrocytes or microglia. Inserts in (C) and (D) shows enlarged view of boxed regions showing FAS-positive
oligodendrocytes (judged by their nuclear morphology). The oligodendrocyte in (D) contains an inclusion. E, FAS-positive glial cells in the cerebellar
white matter. Boxed region in (E) is enlarged in (F) showing oligodendrocytes. G, FAS-positive cells in the pons. Arrow indicates a FAS-positive glial
cell resembling a GCI-bearing oligodendrocyte. Arrowheads indicate FAS-positive astrocytes and microglia. Boxed region in (G) is enlarged in (H). I,
Brain tissue (precentral gyrus white matter) from human MSA (n=8) and control cases (n=10) was sequentially extracted for TBS and SDS soluble
proteins and the SDS soluble fraction were used for further analysis. Four MSA and four control cases are shown. Proteins (20 mg) were resolved by
SDS-PAGE and analyzed by immunoblotting using antibodies against a-syn, p25a and FAS. Actin was included as a loading control. The molecular
sizes (kDa) of the presented bands are indicated to the left. There was a significant increase in SDS-soluble FAS protein in MSA cases compared to
controls (p= 0.043).
doi:10.1371/journal.pone.0055243.g003
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microscope. Images were acquired with FluoUp Mercator
software (Explora Nova) and LSM10 Meta (Zeiss), respectively.
Human brain samples
Approval was obtained to assess frozen brain tissue from MSA
cases (n=13) and age-matched controls (n=15), collected with
consent and ethics approval through the Australian Brain Bank
Network. MSA cases were autopsy confirmed and controls had no
significant neuropathology and no evidence of neurological or
psychiatric disease. All cases were collected within 36 hrs of death
(average of 15611 hrs). The average age of the MSA group was
6868 years with average disease duration of 762 years. The
average age of the control group was 76610 years and was not
different from the MSA group (p=0.17).
Immunohistochemistry
Tissue was sampled from frontal, temporal and parietal
association and primary cortices, basal ganglia, basal forebrain
and brainstem. Sections were deparaffinized in xylene, rehydrated
through serial changes of ethanol gradients and boiled in citrated
Figure 4. FAS colocalizes with p25a and a-synuclein in human MSA brain. Double labeling immunofluorescence using FAS (red) and p25a
(green) antibodies (A–F) and FAS (red) and a-syn (green) antibodies (G–L) in putamen of an MSA case. Protein colocalization is shown as yellow in
merged images (C, F, I, L). A–C, Identification of p25a-positive/FAS-negative GCIs (arrows) in oligodendroglia. D–F, Colocalization of FAS and p25a
within GCI-like structures but not in small punctate cytoplasmic granules. G–L, FAS and a-syn colocalized in 4% of the GCIs (J–L) but the majority of a-
syn-positive GCIs did not colocalize FAS (G–I, arrows indicate a-syn-positive/FAS-negative inclusions).
doi:10.1371/journal.pone.0055243.g004
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buffer containing 1 mM EDTA, pH 8.0, for 10 min. Endogenous
peroxidase was blocked by incubating sections in 1% H2O2/50%
methanol for 10 min. Sections were blocked with 20% normal
horse serum for 1 h and incubated overnight at RT with anti-FAS
(1:40) (NovaCastra, Newcastle, UK) diluted in TBS pH 7.4
containing 1% normal horse serum. Sections were subsequently
incubated with secondary antibody (biotinylated donkey-anti-
mouse antibody) for 1.5 h, Vectastain ABC (Vector Labs) for 1 h
and developed in DAB solution (SigmaFast) for 10 min. Sections
were counterstained with haematoxylin, dehydrated and cover-
slipped.
Double-labeling immunofluorescence was performed on
10 mm-thick formalin-fixed paraffin-embedded sections from the
putamen. The primary antibodies were mouse monoclonal anti-a-
syn (mAb42, Transduction Labs, diluted 1:200), rabbit polyclonal
anti-FAS (C20, Santa Cruz Biotechnology, diluted 1:50) and a rat
polyclonal antibody raised against human p25a (produced in-
house, diluted 1:50). The secondary antibody combinations were
goat anti-mouse Alexa fluor 488 (diluted 1:500) with goat anti-
rabbit Alexa fluor 568 (diluted 1:250) for detecting FAS with either
a-syn or p25a. All primary and secondary antibodies were diluted
in 0.1 M Tris buffer. Sections were first deparaffinized in xylene
and rehydrated in graded ethanols. Antigen retrieval was
performed using 90% formic acid for 3 min (for detection of a-
syn) and boiling in 0.1 M citrate buffer pH 6.0 for 3 min (for FAS
and p25a detection). Sections were pretreated with 5% H2O2/
50% ethanol and 10% normal horse serum in 0.1 M Tris buffer
prior to primary antibody incubation at RT overnight. After
365 min washes in 0.1 M Tris buffer, sections were incubated in
secondary antibody for 2 hrs at RT followed by 365 min washes
with 0.1 M Tris buffer. Sections were coverslipped using
Vectashield mounting medium for fluorescence (Vector Labora-
tories). To determine specificity of the antibodies using these
methods, primary antibody was excluded from the procedure. In
these experiments no labeling was produced. Quantification of
FAS immunoreactivity was determined in two types of GCIs: those
with large, bright, obvious p25a immunoreactivity and those with
a-syn immunoreactivity. Double-labeling fluorescent images were
captured using constant settings on a Nikon Microscope ECLIPSE
90i confocal microscope with a Nikon D-ECLIPSE C1 high-
resolution camera to ensure adequate image processing for
evaluation. 404 large, bright p25a-positive GCIs were evaluated
for colocalisation with FAS. 374 a-syn-positive GCIs were
evaluated for colocalization with FAS as well as for FAS
immunoreactivity within but remote to the a-syn-positive GCIs
in cells.
Frozen tissue sampling and fractionation
Half of the hemisphere was freshly sectioned and frozen blocks
stored at 280uC prior to fractionation. 100–200 mg of frozen
brain tissue from white matter under the precentral gyrus (as this
region contains GCIs but does not contribute to clinical
presentation and is without substantial atrophy and degeneration)
was used. Tissue was homogenized in 10x vol of TBS-homoge-
nisation buffer [50 mM Tris, 125 mM NaCl pH 7.4, 5 mM
EDTA, 0.02% NaN3, 1X protease inhibitor cocktail (Roche)],
sonicated 2610 s on ice and then cleared by centrifugation at
120,000 g for 2 hrs at 4uC. The supernatant was referred to as the
TBS-soluble extract. The pellet was washed twice with homoge-
nization buffer, resuspended in 10x vol solubilisation buffer with
5% SDS, sonicated for 2610 s and centrifuged at 100,000 g for
30 min at 23uC. The supernatant was referred to as the SDS
soluble fraction. All protein concentrations were determined using
the BCA method.
Quantitative Western Blotting
Standard Western blotting methods were used for quantifying
the relative amounts of FAS, p25a and a-syn proteins in SDS
soluble protein fractions from human MSA and control brains.
20 mg of SDS-soluble protein was denatured at 70uC for 10 min
and separated by SDS-PAGE. Proteins were then transferred onto
polyvinylidene difluoride (PVDF) membranes (BioRad Laborato-
ries). The membranes were blocked with 5% powdered skim milk
in TBS-T (10 mM Tris-HCl, pH 7.5, 150 mM NaCl and 1%
Tween-20) for 1 h. Membranes were probed overnight at 4uC
using primary antibodies diluted in blocking buffer (monoclonal
mouse anti-a-syn at 1:4000 (BD Transduction Labs), polyclonal
rabbit anti-FAS (Santa Cruz Biotechnology) at 1:2000, polyclonal
rabbit anti-p25a at 1:12,000 [17], and monoclonal mouse anti-b-
actin at 1:50,000 (Sapphire Biosciences)). Membranes were
washed three times in TBS-T buffer and probed with HRP-
conjugated secondary antibodies diluted in blocking buffer for 1 h.
Immunoreactivity was visualized by chemiluminescence using an
ECL detection system captured onto Hyperfilm. Films were
scanned and the intensity of each band was quantified using NIH
Image J software (National Institutes of Health) with expression
normalized to b-actin Statistical differences were analyzed using
SPSS (IBM SPSS Statistics 18) and a p value less than 0.05
accepted as significant. Group comparisons were performed using
Mann Whitney U tests and correlations between variables were
performed using Spearman Rho tests.
Results
a-synuclein-dependent degeneration in oligodendroglial
cells involves FAS signaling
We coexpressed human p25a and human a-syn in the rat
oligodendrocyte OLN cell line to model the situation observed in
dystrophic oligodendrocytes in MSA [9]. As already described the
coexpression caused a rapid a-syn-dependent degeneration that
was followed by a protracted presentation of characteristics of
apoptosis where the rapid cytoskeletal changes and the ensuing
apoptotic characteristics were ameliorated by a caspase-3 inhibitor
[19]. Active caspase-3 is a downstream effector caspase in the
apoptotic pathway that is activated by upstream caspases as part of
different signaling pathways, e.g. caspase-9 as part of the
mitochondrial pathway and caspase-8 by ligand binding to
Table 1. Expression of FAS within p25a- or a-synuclein-
positive oligodendrocytes in MSA.
Oligodendrocytes containing: FAS+ FAS2
p25a+ inclusions 210 (52%) 194 (48%)
FAS within inclusions 210 (100%)
a-syn+ inclusions 58 (15%) 316 (85%)
FAS within inclusions 15 (4%)
Human MSA brain tissue was analyzed for the presence of either FAS and p25a or
FAS and a-syn using double immunofluorescense microscopy. A total of 404 p25a
positive GCIs were identified and the presence of FAS colocalizing with p25a within
the GCIs or FAS localized outside in the cytoplasm was determined by visual
inspection. Similarly, 374 a-syn-positive GCIs were identified and scored as
described above for colocalization with FAS or for the presence of FAS outside the
GCIs in the cytoplasm.
doi:10.1371/journal.pone.0055243.t001
FAS in Multiple System Atrophy
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e55243
membrane-associated death domain receptors like FAS (reviewed
in [21,22]).
The involvement of caspase-8 and -9 in the activation of
caspase-3 in this model was investigated by treating the cells with
20 mM of the peptide aldehyde inhibitors DEVD, IETD and
LEHD, which are specific for caspase-3, -8, and -9, respectively.
DEVD and IETD protected the cells from degeneration as
demonstrated by a significant reduction in the number of
transfected cells with MT retraction in contrast to LEHD that
did not protect the cells (Fig. 1). This indicates that caspase-8 and
caspase-3 are involved in p25a-induced degeneration in OLN-t40-
AS cells. To corroborate that the caspase-8 dependency was due to
an activation of FAS, we treated the cells with anti-FAS antibody
ZB4, which acts as an antagonist to FASL binding to FAS.
Pretreating the cells with ZB4 reduced the degeneration by
approximately 45% (Fig. 1). This effect was dose–dependent, but
could not be further enhanced (data not shown). These data
demonstrate that activation of the death domain receptor FAS and
downstream activation of caspase-8 and caspase-3 participate in
the p25a-stimulated a-syn-dependent degeneration in oligoden-
drocytes.
a-synuclein expression sensitizes primary
oligodendrocytes to FAS ligand-dependent cytotoxicity
p25a is normally expressed in oligodendrocytes from the stage
of myelination as demonstrated in vivo and during in vitro
differentiation [23,24,25,26]. By contrast, oligodendroglial a-syn
expression occurs only in MSA and the presence of GCIs
hallmarks this disease [27]. The oligodendroglial demise in MSA
occurs gradually and discrete stages of dystrophic oligodendrocytes
can be distinguished where expression of non-aggregated a-syn
precedes the late aggregate-containing stage [9]. To investigate if
FAS activation can be an active player in the pathophysiology of
MSA, we derived enriched oligodendroglial cultures [20] from
newborn (PLP)- a-syn mice [28]. These mice develop normally
and display normal viability, although a-syn-expressing oligoden-
drocytes are sensitized to oxidative stress [7]. a-Syn was expressed
and diffusely distributed throughout the cytoplasm in these
cultures at all stages from the A2B5-positive or NG2-positive
bipolar oligodendrocyte precursors, the O4 positive precursors to
the MBP-positive, mature oligodendrocytes (Fig. 2A). The
specificity of the 15G7 anti-a-syn antibody [29] was demonstrated
by the absence of immunostaining in primary oligodendrocytes
derived from (PLP)-eGFP tg mice (data not shown). Expression of
endogenous p25a in these oligodendrocytes was demonstrated in
oligodendrocyte precursors at 7 DIV (Fig. 2A), but it was also
expressed in the later in vitro developmental stages (data not shown)
in agreement with [24].
Fig. 2B demonstrates a low level of apoptosis in control cells
from (PLP)-a-syn mice and the control strain (PLP)-eGFP as
determined by Hoechst staining, which identified apoptotic cells.
Challenging these primary oligodendrocytes with the ineffective,
soluble form of FASL (sFASL) [30] did not stimulate apoptosis
under these conditions (Fig. 2B). In contrast, an active preparation
of FASL, provided as membranous vesicles (mFASL) [31],
stimulated apoptosis in 47% of control eGFP-expressing oligo-
dendrocytes and 80% of a-syn tg oligodendrocytes (Fig. 2B). Both
were significantly increased compared with the untreated control
cells, but apoptosis induction in the (PLP)-a-syn cells was
significantly higher than in the control (PLP)-eGFP cells (n=3;
p,0.001). The apoptotic potency of mFASL was completely
reversed using a FAS-blocking antibody (Fig. 2B). This corrobo-
rates the specificity of a-syn sensitization to FAS-mediated
apoptosis in cultured oligodendrocytes.
The simplest mechanism by which oligodendrocytes would be
sensitized to the apoptotic effects of FASL is up-regulation of the
FAS receptor. Indeed, cell lysates from a-syn tg oligodendrocytes
showed stronger FAS signal on immunoblot than cell lysates from
control cultures (Fig. 2B, insert).
Expression of FAS is increased in human MSA brain tissue
To validate the possible involvement of oligodendroglial FAS
expression in MSA, we performed immunostaining on brain
sections from neocortical, pontine and cerebellar regions from
human brains. Normal control samples showed only occasional
FAS immunoreactivity in glial cells in white and grey matter
(Fig. 3A and B). By contrast, MSA cases showed numerous FAS-
positive glial cells in both white and grey matter of the
neocortical regions examined (frontal and temporal cortex), pons
and cerebellum (Fig. 3C–H). In white matter regions, as
exemplified by temporal cortex, pons and cerebellum, a robust
labeling of a subset of GCI-bearing oligodendrocytes was evident
along with numerous FAS-positive microglia and astrocytes
(Fig. 3D and G–H). The immunostaining was specific as
omission of primary antibody completely abrogated the staining
(data not shown).
Increased expression of FAS was confirmed by immunoblotting
of SDS-soluble extracts of brain homogenates from MSA cases
and control subjects. All MSA cases had typical clinical disease
and an average disease duration from diagnosis [32]. All had
pathological a-syn-positive GCIs and an increase in SDS-soluble
a-syn (Fig. 3I) consistent with previous literature [33]. A 45kD
band representing FAS was observed and quantified. There was a
significant increase (p=0.043) in SDS-soluble FAS protein in MSA
cases compared to controls (Fig. 3I). FAS levels among MSA cases
did not correlate with a-syn tissue levels.
Assessment of FAS, p25a and a-synuclein in GCIs in MSA
We have previously identified inclusions positive for p25a but
negative for a-syn in approximately 50% of oligodendrocytes in
MSA and a-syn-positive inclusions in the remaining oligodendro-
cytes [9]. The latter a-syn-positive cells (50%) are heterogeneous
with around 60% coexpressing a-syn and p25a and the remainder
expressing only a-syn. In the present study, we identified GCIs as
either p25a-positive (Fig. 4A–F, arrows indicate p25a-positive/
FAS-negative cells) or a-syn-positive in oligodendroglia (Fig. 4G–
L). The p25a positive GCIs displayed two types of morphology, i)
bright thin accumulations close to the nuclear membrane (Fig. 4E)
or ii) more massive accumulations extending into the cytoplasm
(Fig. 4B). By contrast, a-syn-positive inclusions displayed a
morphology that resembles the massive p25a-positive inclusions
(Fig. 4H, K). FAS was predominantly present as intense
perinuclear labeling that extended into the cytoplasm as well as
small punctate cytoplasmic granules (Fig. 4A, D, G, J). Double
labeling immunofluorescence showed FAS and p25a immunore-
activity overlapping predominantly within perinuclear p25a-
positive GCIs and to some extend in the more extensive
cytoplasmic accumulations. However, p25a was not present in
small FAS-immunopositive cytoplasmic granules in pathological
oligodendrocytes, which resembles FAS staining of oligodendro-
cytes in MS lesions [34]. Double labeling immunofluorescence
demonstrated that FAS and a-syn rarely colocalized within GCIs
(Fig. 4I, L) but FAS was present in some oligodendrocytes
harboring a-syn positive GCIs. Quantification of p25a-positive
GCIs revealed that approximately 50% contained FAS immuno-
reactivity (Table 1). In contrast, the majority of oligodendrocytes
with a-syn-positive GCIs (85%) did not contain FAS immunore-
activity (Fig. 4G–I, arrows indicate a-syn-positive/FAS-negative
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cells). Among oligodendroglia with a-syn-immunopositive GCIs,
11% contain FAS immunoreactivity outside the inclusion (Fig. 4G–
I) while a-syn and FAS colocalized in only 4% of the GCIs (Fig. 4J–
L and Table 1). Conclusively, FAS is frequently expressed in p25a-
positive GCIs but only rarely in a-syn-positive GCIs. However, in
the group of a-syn-immunopositive oligodendrocytes, FAS is
mainly expressed outside the GCIs.
Discussion
The mechanisms and signaling pathways involved in the
degeneration of oligodendrocytes and neurons in MSA are still
unclear although the aberrant accumulation of aggregated a-syn
in oligodendroglial GCIs points to a central role of this molecule.
This hypothesis has been corroborated by tg mouse studies where
oligodendroglial expression of human a-syn causes overt neuro-
degeneration or sensitizes oligodendrocytes to the toxin 3-
nitropropionic acid [4,5,6]. p25a is a protein that is expressed
during oligodendrocyte differentiation from the state of myelina-
tion [23] and it stimulates a-syn aggregation in vitro [17]. Rat
OLN-93 oligodendroglial cells express neither endogenous a-syn
nor p25a but coexpression of the two proteins in these cells
allowed cellular modeling of MSA-like degeneration that required
both aggregation and phosphorylation at Ser129 of a-syn [19].
Using peptide inhibitors of caspase-3, -8 and -9, we demonstrate
that caspase-8 and -3 inhibition potently protected the cells. FAS
(CD95) is a death domain receptor that is activated by FASL, a
transmembrane protein or as a soluble ligand depending upon
proteolytic cleavage. FAS is capable of indirectly activating
procaspase-8 and in the current study blocking FAS activation
by the ZB4 antibody also protected the oligodendrocytes,
demonstrating that a-syn aggregation initiates a cell autonomous
autocrine signaling loop in the cell model.
Our hypothesis that coexpression of a-syn and p25a sensitizes
oligodendrocytes to FAS-dependent apoptosis was investigated
using primary oligodendrocytes cultured from oligodendrocyte
precursors from tg mice expressing a-syn [4] or the control protein
eGFP under the oligodendrocyte-specific PLP promoter. PLP-a-
syn mice demonstrate a series of MSA-like abnormalities and show
increased sensitivity to chemical stress, but no overt neurodegen-
eration [4,7,35]. The basal level of apoptosis was low in both a-syn
and eGFP tg oligodendrocytes. However, treatment with micro-
somal preparations containing FASL induced a 40% increase in
apoptosis in a-syn-expressing oligodendrocytes as compared to
eGFP–expressing control cells. Apoptosis could be almost com-
pletely blocked by supplementing the cultures with FAS-blocking
ZB4 antibody as observed for the OLN-93 model. The protective
effect of blocking FAS signaling in the cellular MSA models
resembles the in vivo protective effect of soluble FAS on
oligodendrocytes after acute spinal cord injury in mice [36] and
rat models [37]. Hence, in vivo trials will be justified attempting to
block oligodendroglial FAS signaling in tg MSA mouse models
either using FAS blocking therapeutics e.g. antibodies and soluble
FAS, or crossing the MSA mice models with mice deficient in
components of the FAS signaling system [16].
Post mortem MSA brain tissue is hallmarked by a-syn-
containing GCIs and also characterized by neuron loss, myelin
pallor and gliosis and thus represents the result of a complex
degenerative process. We demonstrate for the first time that FAS
expression is increased in neocortical, cerebellar and pontine MSA
tissue from both grey and white matter with strong staining in
oligodendrocytes and also in astrocyte- and microglia-like cells.
We previously proposed a staging of GCI development in the
course of MSA-associated oligodendroglial degeneration [9]. This
staging is based on dividing GCIs into four stages representing the
progressive accumulation of 1) p25a (approximately 50%),
followed by 2) a-syn (approximately 25%), which subsequently is
transformed into 3) amyloid-type aggregates (approximately 7%).
Finally, the cells shrinks 4) and lose p25a expression (13%). Here
we demonstrate that FAS is present in 50% of oligodendrocytes
harboring p25a-positive inclusions where FAS and p25a coloca-
lize within the inclusions. The localization of FAS within the thin
perinuclear p25a-positive GCIs, likely representing type 1
inclusions, indicates that FAS is expressed early in the degener-
ative process of the oligodendrocyte. This is corroborated by low
FAS expression in oligodendrocytes with a-syn-positive GCIs
(types 2–4).
Human MSA brain tissue retains its number of oligodendro-
cytes despite the pronounced nerve cell loss and astrogliosis, which
is suggestive of an enhanced turnover of oligodendrocytes from
oligodendroglial precursor cells [38]. The predominant expression
of FAS on oligodendrocytes exhibiting early stage type 1 GCIs
may indicate that FAS activation could be an active player
priming the oligodendrocytes for degeneration as observed in
active MS lesions with enhanced FAS expression [34]. Early FAS
stimulation can hypothetically contribute to the overall demise of
the cell but also to the enigmatic expression of a-syn in
oligodendrocytes, either by enhanced cellular uptake from the
extracellular fluid or by activating a-syn gene expression. This
may be similar to the enhanced a-syn expression in substantia
nigra neurons adjacent to degenerating neurons in a striatal lesion
model. This model has provided evidence that soluble mediators
from degenerating cells can stimulate a-syn expression [39].
The mechanism behind the neuronal loss in MSA is not clear
but the enhanced expression of FAS early in GCI formation along
with the expression in astrocytes and microglia, suggests that FAS
mediated signaling may contribute to a broader prodegenerative
tissue remodeling e.g. via inflammatory NF-kB activation [40].
In conclusion, MSA-associated neurodegeneration is associated
with FAS expression in oligodendrocytes displaying early GCI
lesions along with astrocytes and microglia. Mechanistically, a-syn
tg cell line and oligodendrocyte models of MSA display an
enhanced sensitivity to FAS dependent signaling. This suggests
that manipulation of this signaling system may hold promise as a
therapeutic target in this yet intractable disease.
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